In our cohort with rather mild steatosis, we found modest but significant downregulation of MAT1A and MAT2B. Together with other findings, our data indicate that the expression of these genes may serve as one of the indicators of NAFLD progression. The gene discussed is MAT1A; the disease is metabolic dysfunction-associated steatotic liver disease.